PhaseBio Pharmaceuticals, Inc.
PHAS · NASDAQ
6/30/2022 | 3/31/2022 | 12/31/2021 | 9/30/2021 | |
|---|---|---|---|---|
| Revenue | $208 | $117 | $158 | $335 |
| % Growth | 77.8% | -25.9% | -52.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $208 | $117 | $158 | $335 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $20,939 | $14,336 | -$74,650 | $25,066 |
| G&A Expenses | $4,581 | $4,009 | -$11,181 | $3,845 |
| SG&A Expenses | $4,581 | $4,009 | -$11,181 | $3,845 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $25,520 | $18,345 | -$85,831 | $28,911 |
| Operating Income | -$16,549 | -$10,993 | $85,470 | -$28,576 |
| % Margin | -7,956.3% | -9,395.7% | 54,094.7% | -8,530.1% |
| Other Income/Exp. Net | $8,647 | $7,087 | $762 | -$3,348 |
| Pre-Tax Income | -$16,665 | -$11,141 | $86,232 | -$31,924 |
| Tax Expense | $116 | $148 | -$1,598 | $0 |
| Net Income | -$16,781 | -$11,289 | $87,830 | -$31,924 |
| % Margin | -8,067.8% | -9,648.7% | 55,588.6% | -9,529.6% |
| EPS | -0.34 | -0.23 | 1.82 | -0.66 |
| % Growth | -47.8% | -112.6% | 375.8% | – |
| EPS Diluted | -0.34 | -0.23 | 1.82 | -0.66 |
| Weighted Avg Shares Out | 49,183 | 48,635 | 48,131 | 48,046 |
| Weighted Avg Shares Out Dil | 49,183 | 48,635 | 48,131 | 48,046 |
| Supplemental Information | – | – | – | – |
| Interest Income | $17 | $3 | $11 | $4 |
| Interest Expense | $116 | $148 | $762 | $222 |
| Depreciation & Amortization | $603 | $601 | $606 | $130 |
| EBITDA | -$15,946 | -$10,392 | $86,076 | -$31,572 |
| % Margin | -7,666.3% | -8,882.1% | 54,478.2% | -9,424.5% |